Camurus has carried out a directed share issue

The board of directors of Camurus has, based on an authorization to issue shares granted by the 2023 annual general meeting, resolved on a directed issue of 2,000,000 new shares at a subscription price of SEK 545 per share, consequently raising gross proceeds of SEK 1,090 million before deduction of transaction costs.

The subscription price in the directed issue was determined through an accelerated book-building procedure directed to Swedish and international professional and institutional investors.

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.

Camurus was advised by Mannheimer Swartling in connection with the share issue.